[Table/Fig-3]:
Comparative in vitro activity of six β-lactam/β-lactamase inhibitor combinations for ESBL organisms Abbreviations: Amoxy/clav-Amoxycillin-clavulanic acid, Amp/sul-Ampicillin-sulbactam, Cefo/sul-Cefoperazone-sulbactam, Pip/taz-Piperacillin- tazobactam, Cfp/taz-Cefepime-Tazobactam, Ticar/clav-Ticarcillin/clavulanic acid, ESBL-extended spectrum beta lactamase
| Organism | Total | ESBL isolates (%) | Amox/clav | Amp/sul | Cefo/sul | Pip/taz | Cfp/taz | Ticar/clav |
|---|---|---|---|---|---|---|---|---|
| Escherichia coli | 185 | 57(30.81%) | 9(15.78%) | 5(8.77%) | 54(94.73%) | 31(54.38%) | 57(100%) | 13 (54.38%) |
| Klebseilla pneumoniae | 64 | 10(15.62%) | 1(10%) | 1(10%) | 9(90%) | 6(60%) | 10(100%) | 2(20%) |
| Total | 249 | 67(26.90%) | 10(14.92%) | 6(8.95%) | 63(94.02%) | 37(55.22%) | 67(100%) | 15(22.38%) |